Hormone therapy for transgender patients

Cécile A Unger, Cécile A Unger

Abstract

Many transgender men and women seek hormone therapy as part of the transition process. Exogenous testosterone is used in transgender men to induce virilization and suppress feminizing characteristics. In transgender women, exogenous estrogen is used to help feminize patients, and anti-androgens are used as adjuncts to help suppress masculinizing features. Guidelines exist to help providers choose appropriate candidates for hormone therapy, and act as a framework for choosing treatment regimens and managing surveillance in these patients. Cross-sex hormone therapy has been shown to have positive physical and psychological effects on the transitioning individual and is considered a mainstay treatment for many patients. Bone and cardiovascular health are important considerations in transgender patients on long-term hormones, and care should be taken to monitor certain metabolic indices while patients are on cross-sex hormone therapy.

Keywords: Hormone therapy; cross-sex hormones; gender dysphoria; transgender.

Conflict of interest statement

The author has no conflicts of interest to declare.

References

    1. Reiner WG, Gearhart JP. Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. N Engl J Med 2004;350:333-41. 10.1056/NEJMoa022236
    1. Meyer-Bahlburg HF. Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation. Arch Sex Behav 2005;34:423-38. 10.1007/s10508-005-4342-9
    1. Zhou JN, Hofman MA, Gooren LJ, et al. A sex difference in the human brain and its relation to transsexuality. Nature 1995;378:68-70. 10.1038/378068a0
    1. Gates GJ. How Many People are Lesbian, Gay, Bisexual and Transgender? The Williams Institute, 2011.
    1. Conron KJ, Scott G, Stowell GS, et al. Transgender health in Massachusetts: results from a household probability sample of adults. Am J Public Health 2012;102:118-22. 10.2105/AJPH.2011.300315
    1. Leinung MC, Urizar MF, Patel N, et al. Endocrine treatment of transsexual persons: extensive personal experience. Endocr Pract 2013;19:644-50. 10.4158/EP12170.OR
    1. World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people. 7th ed; 2011. Available online: (Accessed on 10 May 2016).
    1. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-54. 10.1210/jc.2009-0345
    1. Gardner IH, Safer JD. Progress on the road to better medical care for transgender patients. Curr Opin Endocrinol Diabetes Obes 2013;20:553-8. 10.1097/01.med.0000436188.95351.4d
    1. Nakamura A, Watanabe M, Sugimoto M, et al. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J 2013;60:275-81. 10.1507/endocrj.EJ12-0319
    1. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000;85:2913-21. 10.1210/jcem.85.8.6710
    1. Dittrich R, Binder H, Cupisti S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005;113:586-92. 10.1055/s-2005-865900
    1. Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164:635-42. 10.1530/EJE-10-1038
    1. Wilson R, Spiers A, Ewan J, et al. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas 2009;62:281-6. 10.1016/j.maturitas.2009.01.009
    1. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25. 10.1210/jc.2007-1809
    1. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012;9:2641-51. 10.1111/j.1743-6109.2012.02876.x
    1. Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol 2016. [Epub ahead of print]. 10.1016/S2213-8587(16)00036-X
    1. Costantino A, Cerpolini S, Alvisi S, et al. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther 2013;39:321-35. 10.1080/0092623X.2012.736920
    1. Gooren LJ. Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes 2014;21:233-8. 10.1097/MED.0000000000000064
    1. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med 2012;9:531-41. 10.1111/j.1743-6109.2011.02564.x
    1. Kranz GS, Wadsak W, Kaufmann U, et al. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biol Psychiatry 2015;78:525-33. 10.1016/j.biopsych.2014.09.010
    1. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis 2013;52:49-65. 10.1016/j.nbd.2012.06.001
    1. Colizzi M, Costa R, Pace V, et al. Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style. J Sex Med 2013;10:3049-58. 10.1111/jsm.12155
    1. Behre HM, Wang C, Handelsman DJ, et al. Pharmacology of testosterone prepartions. In: Nieschlag E, Behre HM. editors. Testosterone, action, deficiency, substitution. Cambridge University Press, 2004:405-44.
    1. Callewaert F, Sinnesael M, Gielen E, et al. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol 2010;207:127-34. 10.1677/JOE-10-0209
    1. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 2012;97:2503-11. 10.1210/jc.2012-1187
    1. Mueller A, Zollver H, Kronawitter D, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2011;119:95-100. 10.1055/s-0030-1255074
    1. Gooren LJ, Giltay EJ. Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. Andrologia 2014;46:570-5. 10.1111/and.12111
    1. Wierckx K, Elaut E, Van Caenegem E, et al. Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration. Eur J Endocrinol 2011;165:331-7. 10.1530/EJE-11-0250
    1. Asscheman H, T'Sjoen G, Lemaire A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia 2014;46:791-5. 10.1111/and.12150
    1. Spack NP. Management of transgenderism. JAMA 2013;309:478-84. 10.1001/jama.2012.165234
    1. Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol 2013;169:471-8. 10.1530/EJE-13-0493
    1. Roberts TK, Kraft CS, French D, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med 2014;127:159-62. 10.1016/j.amjmed.2013.10.009
    1. Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health 2013;103:943-51. 10.2105/AJPH.2013.301241
    1. Sanchez NF, Sanchez JP, Danoff A. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health 2009;99:713-9. 10.2105/AJPH.2007.132035
    1. Mepham N, Bouman WP, Arcelus J, et al. People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. J Sex Med 2014;11:2995-3001. 10.1111/jsm.12691
    1. de Haan G, Santos GM, Arayasirikul S, et al. Non-Prescribed Hormone Use and Barriers to Care for Transgender Women in San Francisco. LGBT Health 2015;2:313-23. 10.1089/lgbt.2014.0128

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren